We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Tools
Register for streaming realtime charts, analysis tools, and prices.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Smith & Nephew Plc | LSE:SN. | London | Ordinary Share | GB0009223206 | ORD USD0.20 |
| Price Change | % Change | Share Price | Shares Traded | Last Trade
|
|
|---|---|---|---|---|---|
| 12.00 | 1.17% | 1,035.50 | 2,062,484 | 16:35:10 |
| Bid Price | Offer Price | High Price | Low Price | Open Price | |
|---|---|---|---|---|---|
| 1,033.50 | 1,034.50 | 1,037.50 | 1,026.50 | 1,026.50 | |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Ortho,prosth,surg Appl,suply | USD 5.22B | USD 223M | USD 0.2553 | 40.50 | 9.03B |
| Last Trade Time | Trade Type | Trade Size | Trade Price | Currency |
|---|---|---|---|---|
| 17:55:14 | O | 49,093 | 1,035.50 | GBX |
| Date | Time | Source | Headline |
|---|---|---|---|
| 01/12/2023 | 11:27 | UKREG | Smith & Nephew Plc Total Voting Rights |
| 29/11/2023 | 07:00 | UKREG | Smith & Nephew Plc Meet the Management Event |
| 22/11/2023 | 09:04 | ALNC |  Smith & Nephew buys sports medicine firm focused on knee repair |
| 22/11/2023 | 07:00 | UKREG | Smith & Nephew Plc Acquisition |
| 14/11/2023 | 15:25 | UKREG | Smith & Nephew Plc Director/PDMR Shareholding |
| 10/11/2023 | 15:30 | UKREG | Smith & Nephew Plc Director/PDMR Shareholding |
| 10/11/2023 | 12:56 | UKREG | Smith & Nephew Plc Director/PDMR Shareholding |
| 09/11/2023 | 17:03 | UKREG | Smith & Nephew Plc Director/PDMR Shareholding |
| 03/11/2023 | 14:30 | UKREG | Smith & Nephew Plc Director/PDMR Shareholding |
| 02/11/2023 | 14:12 | ALNC | CORRECT: Smith & Nephew hires new finance chief as revenue rises |
Smith & Nephew (SN.) Share Charts1 Year Smith & Nephew Chart |
|
1 Month Smith & Nephew Chart |
Intraday Smith & Nephew Chart |
| Smart Money! SN. is a large holding in the following funds: | ||
| Fund | Percentage of Fund | Last Updated |
| BLACKROCK INCOME AND GROWTH INVESTMENT TRUST PLC | 3.00% | 2023-05-31 |
| Date | Time | Title | Posts |
|---|---|---|---|
| 10/11/2023 | 11:07 | *** Smith and Nephew *** | 688 |
| 29/10/2015 | 08:48 | SN. | 122 |
| 10/1/2011 | 13:03 | Smith and Nephew 2008 | 67 |
| 09/1/2011 | 17:12 | Smiths: Charts and News etc. | 296 |
| 25/9/2006 | 14:09 | Smith&Nep. Why the rise? | 75 |
| Trade Time | Trade Price | Trade Size | Trade Value | Trade Type |
|---|---|---|---|---|
| 2023-12-01 17:30:22 | 1,031.50 | 134 | 1,382.21 | O |
| 2023-12-01 17:30:22 | 1,031.04 | 12,075 | 124,498.44 | O |
| 2023-12-01 17:30:22 | 1,033.44 | 670 | 6,924.05 | O |
| 2023-12-01 17:28:56 | 1,034.78 | 875 | 9,054.32 | O |
| 2023-12-01 17:20:23 | 1,033.75 | 116 | 1,199.15 | O |
| Top Posts |
|---|
Posted at 02/12/2023 08:20 by Smith & Nephew Daily Update Smith & Nephew Plc is listed in the Ortho,prosth,surg Appl,suply sector of the London Stock Exchange with ticker SN.. The last closing price for Smith & Nephew was 1,023.50p.Smith & Nephew currently has 873,383,055 shares in issue. The market capitalisation of Smith & Nephew is £9,030,780,789. Smith & Nephew has a price to earnings ratio (PE ratio) of 40.50. This morning SN. shares opened at 1,026.50p |
Posted at 10/11/2023 11:07 by philanderer Goldman Sachs starts Smith & Nephew with 'buy' - price target 1,400 pence |
Posted at 14/10/2023 08:00 by knighty0001 That price has to have factored in the Q3 results, surely we wont see it dip below £9!? |
Posted at 13/10/2023 13:45 by justiceforthemany June 2022Trauma and orthopaedic equipment provider Smith & Nephew’s shares are trading “35% below their peak”, the bank said, partly due to the impact of Covid-19 on hospital activity, while its balance sheet is “only modestly geared at 1.6x EBITDA”. RBC said a consortium of buyers might opt to divest the company's wound care business for a partial return, but with such a hefty price tag, the asset would be likely to come back to the public markets in future. “A re-IPO could be the potential exit route for PE,” it said. |
Posted at 13/10/2023 11:43 by essentialinvestor Might be worth looking at what the CEO does.. ?His large sales at £12.74 and £12.78 now look very astute. 5 different CEO's in 10 years, eh A rating of 16 X forward looks more than fair for SN. in a post ZIRP world. The market might see it differently, but that's how it looks to me. |
Posted at 12/10/2023 14:36 by lonrho 2010 seems to be the peak year with a trading profit of 969k and a margin of 24.4% compared to 2022 with 901k trading profit and a margin of 17.2%. Rupert Soames did a good job of sorting out Serco so hopefully he can make a difference now he is chairman here. By mid 2014 share price was £11 despite profits reducing from 2010 onwards. |
Posted at 12/10/2023 13:58 by essentialinvestor Laurence, part of the issue is arguably their main competitors growing strongerv SN over the last decade. This may account for some of SN's weaker metrics. While a bid can't be ruled out, it has been mentioned as a takeover candidate for decades. If you go back 10 years, this was a high margin business with low gearing and a prodigious cash generator. Those bullish on SN may say that's now reflected in the current share price, however circa 2013, at approx £8 plus a share you were buying at the time a great business. |
Posted at 12/10/2023 08:01 by essentialinvestor How are margins stable?, trading profit margin registered a hefty fall at the H1 to15.3%. For years SN had trading profit margins in excess of 20%, for a few years around 24/25%. Margins began a multi year decline around 2015/16 (from memory) and despite multiple CEO's since, each with a new refreshed strategy to improve business performance, results have arguably been sadly lacking. Margin compression leading to reduced free cash flow is central to the bearish case on SN. |
Posted at 27/9/2023 19:00 by pugugly Too many of those needing our product - in particular hips in the UK - having operations delayed - once twice or more times by the medics who have abandoned the Hippocratic Oath and are holding the NHS to ransom and condemning too many of the mainly elderly to ongoing pain which could be relieved by surgery.Results - Significant number of possible beneficiaries pass over in pain before they can receive an operation so no longer potential beneficiaries - fall in usage reduces S&N revenue and cash flow = fall in share price - takeover potential and yet another British company crosses the ocean reducing GB plc's revenue and tax base. Not yet low enough (imo) to attract a bid - Could easily need to drop another 10%+ or so.; |
Posted at 18/8/2023 08:01 by pugugly Looks as though going to hell on a broomstick -All brokers targets well under water - Any value - ie:- share price growth potential - peg and p/e seem very high given share price history. Share price at time of posting 1072p .Smith & Nephew Broker views Date Broker Recomm. Old target price New target price Notes 20/07/2023 JP Morgan Cazenove Neutral - - Reiteration 03/07/2023 JP Morgan Cazenove Neutral - 1,612.00p Reiteration 15/06/2023 Citigroup Buy - - Reiteration 16/05/2023 Berenberg Bank Buy 1,400.00p 1,500.00p Reiteration 02/05/2023 Berenberg Bank Buy 50.00p 60.00p Reiteration 27/04/2023 Barclays Underweight 1,100.00p 1,200.00p Reiteration 14/03/2023 Citigroup Buy - - Reiteration 08/03/2023 Berenberg Bank Buy - 1,400.00p Reiteration 01/03/2023 Liberum Capital Buy 1,120.00p 1,410.00p Upgrade 17/11/2022 Berenberg Bank Buy 1,400.00p 1,400.00p Reiteration |
Posted at 06/9/2022 07:48 by roguetraderuk unless share price were to move up 10% or more then v v unlikely any rns. in any case i think its a passive stake build. any offer is likely going to have to be over 15/16 quid here and its not a level the board will accept at this point. next year i think that that price will be more acceptable. not necessarily because the share price will be much lower at that time (i dont think they go much below 10 maybe to 950 but if they do then 8 is quite prob in that case) but the longer the share price is lower than the more pressure the board will be under to accept a price around 15/16. personally think its still a lot of money to pay inc of all debt so its only the americans that could be interested. |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
|
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions Support: +44 (0) 203 8794 460 | support@advfn.com |
| ADVFN UK Investors Hub ADVFN Italy ADVFN Australia ADVFN Brazil |
| ADVFN Canada ADVFN Germany ADVFN Japan ADVFN Mexico |
| ADVFN France ADVFN US ADVFN Korea |
